Various studies suggested that cytotoxicity induced by 5-fluorouracil (5-FU) is an apoptotic mechanism possibly mediated by the Fas/FasL system. In this preliminary work, we studied retrospectively the role the Fas/FasL expression as a predictive response factor with fluoropyrimidine-based chemotherapies. We developed a real-time PCR method for measuring Fas and FasL expression in various biopsies from patients treated with a FUFOL-like protocol. No correlation was found between Fas or FasL expression and overall survival or partial response. However, the PCR assay was simple and convenient to use for quantitation of Fas/FasL in tumor biopsies.

References

1 White E (1996) Life, death and the pursuit of apoptosis. Genes Development, 10, 1–15.
10.1101/gad.10.1.1
CAS PubMed Web of Science® Google Scholar
2 Nagata S (1997) Apoptosis by death factor. Cell, 88, 355–365.
10.1016/S0092-8674(00)81874-7
CAS PubMed Web of Science® Google Scholar
3 Grem JL (2000) 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investigations on New Drugs, 18, 299–313.
10.1023/A:1006416410198
CAS PubMed Web of Science® Google Scholar
4 Rustum YM, Danhauser L, Wang G (1979) Selectivity of activation of 5-fluorouracil: biochemicals basis. Bulletin du Cancer, 66, 43–47.
CAS PubMed Google Scholar
5 Rustum YM (1979) Multiple determinants of antimetabolites action in humans. Bulletin du Cancer, 66, 93–96.
CAS PubMed Web of Science® Google Scholar
6 Rustum YM, Harstrick A, Cao S et al. (1997) Thymidilate synthase inhibitors in cancer therapy: direct and indirect inhibitors. Journal of Clinical Oncology, 15, 389–400.
10.1200/JCO.1997.15.1.389
CAS PubMed Web of Science® Google Scholar
7 Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer, a tale of two drugs: implications for biochemical modulation. Journal of Clinical Oncology, 15, 368–381.
10.1200/JCO.1997.15.1.368
CAS PubMed Web of Science® Google Scholar
8 Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456–1462.
10.1126/science.7878464
CAS PubMed Web of Science® Google Scholar
9 Tillman D, Petak I, Houghton J (1999) A fas-dependent component in 5-Fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clinical Cancer Research, 5, 425–430.
CAS PubMed Web of Science® Google Scholar
10 Eishorst ST, Muerkoster S, Weigand MA et al. (2001) The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of CD95 (APO-1, Fas) system. Cancer Research, 61, 243–248.
PubMed Web of Science® Google Scholar
11 Friesen C, Fulda S, Debatin KM (1997) Deficient activation of CD95 (APO-1/Fas) system in drug-resistant cells. Leukaemia, 11, 1833–1841.
10.1038/sj.leu.2400827
CAS PubMed Web of Science® Google Scholar
12 Houghton JA, Harwood FG, Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via fas signaling. Proceedings of the National Academy of Sciences USA, 94, 8144–8149.
10.1073/pnas.94.15.8144
CAS PubMed Web of Science® Google Scholar
13 Longley DB, Boyer J, Allen WL et al. (2002) The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Research, 62, 2644–2649.
CAS PubMed Web of Science® Google Scholar
14 Ciccolini J, Peillard L, Evrard A et al. (2000) Enhanced antitumor activity of 5-fluorouracil in combination with 2-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clinical Cancer Research, 6, 1529–1535.
CAS PubMed Web of Science® Google Scholar
15 Van Triest B, Pinedo HM, Peters GJ (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Annals in Oncology, 11, 385–391.
Google Scholar
16 Backus HHJ, Dukers DF, Van Groeningen CJ et al. (2001) 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastasis of colorectal cancer patients. Annals of Oncology, 12, 209–216.
10.1023/A:1008331525368
CAS PubMed Web of Science® Google Scholar
17 Benhattar J, Cerrotini JP, Sarraga E et al. (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. International Journal of Cancer, 69, 190–192.
10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V
CAS PubMed Web of Science® Google Scholar
18 Bunz F, Hwang PM, Torrance C et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. Journal of Clinical Investigation 104, 263–269.
10.1172/JCI6863
CAS PubMed Web of Science® Google Scholar
19 Saas P, Walker PR, Hahne M et al. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immuneprivilege in the brain? Journal of Clinical Investigation 99, 1173–1178.
10.1172/JCI119273
CAS PubMed Web of Science® Google Scholar
20 Walker PR, Saas P, Dietrich PY (1998) Tumor expression of Fas ligand (CD95L) and the consequences. Current Opinion in Immunology, 10, 564–572.
10.1016/S0952-7915(98)80225-2
CAS PubMed Web of Science® Google Scholar
21 Möller P, Koretz K, Leithauser F et al. (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. International Journal of Cancer, 57, 371–377.
10.1002/ijc.2910570314
CAS PubMed Web of Science® Google Scholar
22 Ungefroren H, Voss M, Jansen M et al. (1998) Human pancreatic adenocarcinomas express Fas and FasL yet are resistant to Fas mediated apoptosis. Cancer Research, 58, 1741–1749.
CAS PubMed Web of Science® Google Scholar
23 Higaki K, Yano H, Kojiro M (1996) Fas antigen expression and its relation ship with apoptosis in human hepatocellular carcinoma and non cancerous tissues. American Journal of Pathology, 149, 429–437.
PubMed Web of Science® Google Scholar
24 Gratas C, Tohma Y, Barnas C et al. (1998) Up-regulation of Fas (APO-1/CD95) ligand and downregulation of Fas expression in human esophageal cancer. Cancer Research, 58, 2057–2062.
CAS PubMed Web of Science® Google Scholar
25 Keane MM, Ettemberg SA, Lowrey GA et al. (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Research, 56, 4791–4798.
CAS PubMed Web of Science® Google Scholar
26 Solary E, Micheau O, Dimanche-Boîtrel MT et al. (1998) Le système Fas/FasL: implications dans la réponse immunitaire antitumorale et dans l'activité des agents cytotoxiques. Bulletin du Cancer, 85, 685–694.
CAS PubMed Web of Science® Google Scholar
27 O'Connel J, O'Sullivan GC, Collins JK et al. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Journal of Experimental Medecine, 184, 1075–1082.
10.1084/jem.184.3.1075
CAS PubMed Web of Science® Google Scholar
28 Ciccolini J, Fina F, Bezulier K et al. (2002) Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Molecular Cancer Therapeutics, 11, 923–927.
Google Scholar
29 Backus HHJ, Van Riel JMGH, Van Groeningen CJ et al. (2001) Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Annals in Oncology, 12, 779–785.
10.1023/A:1011112227044
CAS PubMed Web of Science® Google Scholar
30 Sjostrom J, Blomqvist C, von Bogulawski K et al. (2002) The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clinical Cancer Research, 8, 811–816.
CAS PubMed Web of Science® Google Scholar

Citing Literature

All articles

Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?^*

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?*

Summary

References

Citing Literature

References

Related

Information

Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?^*